Ependymoma – Diagnostics – Overview of Information and Clinical Research

Understanding how ependymoma is identified and confirmed can help patients and families navigate the diagnostic journey with more confidence and clarity.

Introduction

Diagnosing ependymoma requires careful attention to symptoms and a series of specialized tests. Anyone experiencing persistent headaches, unexplained nausea and vomiting, or worsening back pain should consider seeking medical evaluation, especially if these symptoms don’t improve with time or basic treatments. Children who become unusually irritable, experience balance problems, or show developmental delays may also need assessment.^[1]

The location of symptoms often provides clues about where the tumor might be. When an ependymoma forms in the brain, it typically causes headaches, dizziness, vision changes, or seizures. If the tumor develops in the spinal cord, people often experience back or neck pain, numbness in their arms or legs, muscle weakness, or changes in bladder and bowel control.^[2] Parents of young children should watch for signs that babies and toddlers cannot express in words, such as a larger than usual head size, unusual fussiness, or vomiting more frequently than normal.^[2]

Anyone with a family history of certain genetic conditions, particularly neurofibromatosis type 2, which is an inherited disorder that affects nerve tissue growth, may face higher risk and should discuss screening with their healthcare provider.^[3] While most ependymomas occur without any clear cause or family pattern, those with these genetic conditions should be especially vigilant about new or changing symptoms.

⚠️ Important

Early diagnosis of ependymoma can significantly improve treatment outcomes. If you or your child experience persistent neurological symptoms such as severe headaches that don’t respond to usual remedies, unexplained weakness, or changes in coordination, don’t delay seeking medical attention. These symptoms may have many causes, but only proper evaluation can determine what’s happening.

Diagnostic Methods

The diagnostic process for ependymoma begins with a thorough medical history and physical examination. Your healthcare provider will ask detailed questions about when symptoms started, how they’ve changed over time, and whether anything makes them better or worse. This conversation helps the doctor understand the full picture of what you’re experiencing.^[5]

A neurological examination is a critical part of the diagnostic process. During this exam, the doctor checks how well your brain and nervous system are functioning. They will test your vision, hearing, balance, coordination, muscle strength, and reflexes. They may also assess your ability to feel sensations and check how you walk and move. Problems identified in specific areas during this exam can point to where in the brain or spinal cord a tumor might be located.^[9]

Imaging tests provide the most detailed information about potential tumors. Magnetic resonance imaging (MRI) is the primary tool used to diagnose ependymoma. This test uses powerful magnets and radio waves to create detailed pictures of the brain and spinal cord. Unlike X-rays, MRI doesn’t use radiation, making it safer for repeated use, especially in children. The images can show the exact size, shape, and location of a tumor. Often, a contrast dye is injected into a vein before the scan to make the tumor stand out more clearly in the images.^[3] Because ependymomas can occur in both the brain and spinal cord, doctors may recommend imaging both areas even if symptoms seem limited to one location.^[9]

On an MRI scan, ependymomas typically appear as one or more well-defined masses that often brighten when contrast dye is used. The tumor’s appearance helps doctors distinguish it from other types of brain or spinal cord tumors, though a biopsy is still needed for confirmation.^[3]

A computed tomography (CT) scan may also be used, particularly in emergency situations or when MRI is not available. CT scans use X-rays taken from many angles to create cross-sectional images of the body. While not as detailed as MRI for soft tissue like brain tumors, CT scans are faster and can be helpful in certain circumstances.^[2]

Testing the cerebrospinal fluid (CSF) is another important diagnostic step. This fluid surrounds and protects the brain and spinal cord. During a procedure called a lumbar puncture or spinal tap, a needle is carefully inserted into the lower back to withdraw a small amount of this fluid. The fluid is then examined in a laboratory to look for tumor cells. This test helps determine if the ependymoma has spread through the CSF to other areas of the brain or spinal cord.^[9] Finding tumor cells in the CSF indicates that the disease has spread beyond the original tumor site, which affects treatment planning.

The definitive diagnosis of ependymoma requires a biopsy, which involves removing a sample of tumor tissue for examination under a microscope. In many cases, doctors obtain this tissue during surgery to remove the tumor, rather than performing a separate biopsy procedure. A specialist called a neuropathologist, who has expertise in examining nervous system tissues, studies the tumor cells carefully to confirm the diagnosis and determine the specific type and grade of ependymoma.^[3]

Once the tumor tissue is obtained, laboratory specialists perform detailed analysis to classify the ependymoma. They examine how the cells look under a microscope and may perform molecular testing to identify specific genetic changes within the tumor. These findings help doctors understand how aggressive the tumor is and guide treatment decisions.^[9]

Grading and Classification

Ependymomas are grouped into grades based on how the cells appear under a microscope and how quickly they’re likely to grow. Grade 1 ependymomas are slow-growing tumors. Two subtypes fall into this category: subependymomas and myxopapillary ependymomas. Subependymomas can arise in the brain or spine and are more common in adults than children. Myxopapillary ependymomas typically develop in the lower part of the spinal cord.^[3]

Grade 2 ependymomas are also considered low-grade tumors, but they are more likely to come back after treatment than grade 1 tumors, especially if the entire tumor cannot be removed during surgery. This grade includes conventional ependymomas that can occur in either the brain or spine.^[3]

Grade 3 ependymomas, also called anaplastic ependymomas, are malignant or cancerous. This means they are fast-growing tumors. They occur most often in the brain but can also develop in the spine. These tumors grow aggressively and often spread to other parts of the brain through the cerebrospinal fluid.^[2]

Modern classification systems now also consider the tumor’s location and molecular features. According to the 2021 World Health Organization classification, ependymomas are divided into ten main subtypes based on where they form in the nervous system and what genetic changes are present in the tumor cells. These subtypes include supratentorial ependymomas (in the upper part of the brain), posterior fossa ependymomas (in the lower back part of the brain), and spinal ependymomas, each with their own molecular characteristics.^[3] This detailed classification helps predict how the tumor will behave better than grade alone.

Diagnostics for Clinical Trial Qualification

When patients consider participating in clinical trials for ependymoma, additional diagnostic procedures may be required beyond those used for standard diagnosis. Clinical trials often have strict criteria for who can enroll, and specific tests help determine if a patient meets these requirements.

Most clinical trials require confirmation of the ependymoma diagnosis through pathology review. This means that tumor tissue samples are sent to specialized laboratories where expert neuropathologists review the diagnosis independently. Sometimes fresh tumor tissue or stored tissue samples from previous surgeries must meet certain requirements for molecular testing.^[3]

Detailed imaging studies are typically required before enrolling in a trial. Baseline MRI scans of both the brain and spine create a starting point for measuring how well a treatment works. These scans must often be performed within a specific timeframe before starting the trial treatment, such as within 30 days of enrollment. The images help researchers determine the exact size and extent of the tumor and provide a comparison for future scans during treatment.^[12]

Molecular and genetic testing of tumor tissue has become increasingly important for clinical trial enrollment. Researchers may need to know if the tumor has specific genetic mutations or molecular features. For example, some trials specifically enroll patients with supratentorial ependymomas that have certain gene fusions, while other trials may focus on spinal ependymomas with specific genetic amplifications.^[3] These tests require adequate tumor tissue, which is why tissue collection and preservation during surgery is so important.

Blood tests and other laboratory assessments ensure patients are healthy enough to tolerate experimental treatments. Standard blood work checks kidney and liver function, blood cell counts, and other indicators of general health. Some trials may require additional specialized blood tests depending on the treatment being studied.^[2]

Functional status assessments evaluate how well patients can perform daily activities. Clinical trials often use standardized scoring systems to measure this, and patients must meet minimum functional levels to enroll. For children, developmental assessments may also be required to understand how the disease and its treatment affect growth and development.

Some trials require documentation that standard treatments have been tried and either failed or are no longer options. This might involve reviewing medical records, pathology reports, and imaging from previous treatments. Researchers want to ensure that experimental treatments are being tested at the appropriate stage of disease.

⚠️ Important

Clinical trials offer access to new treatments that aren’t yet widely available, but they require careful screening and ongoing monitoring. If you’re interested in a clinical trial, discuss this option early with your healthcare team. They can help determine which trials might be appropriate and guide you through the qualification process, which may take several weeks to complete.

Prognosis and Survival Rate

Prognosis

The outlook for people with ependymoma depends on several factors. The tumor’s location plays a significant role in determining outcomes. Spinal ependymomas often have better outcomes than those in the brain because they’re frequently easier to remove completely. The grade of the tumor also matters greatly, with lower-grade tumors generally having better prognoses than higher-grade ones.^[3]

How much of the tumor can be removed during surgery is one of the most important factors affecting prognosis. When surgeons can remove the entire tumor, patients typically have better outcomes and longer periods without the cancer returning. Unfortunately, ependymomas located near critical brain structures or deep within the spinal cord may be impossible to remove completely, which increases the chance of recurrence.^[9]

Age at diagnosis influences outcomes, with younger children, particularly those under three years old, sometimes facing more challenges. However, this depends heavily on tumor location and type. The molecular subtype of the ependymoma, determined through genetic testing of tumor tissue, can predict behavior better than grade alone. Some molecular subtypes are associated with better outcomes, while others tend to be more aggressive.^[3]

Ependymomas can recur even after successful initial treatment. Grade 2 ependymomas are more likely to return than grade 1 tumors, especially if complete surgical removal wasn’t possible. Grade 3 anaplastic ependymomas have the highest risk of recurrence. When tumors do come back, they may appear at the original site or spread to other locations in the brain or spinal cord through cerebrospinal fluid.^[4]

Survival Rate

Survival rates for ependymoma vary significantly based on the factors mentioned above. It’s important to understand that survival statistics are based on large groups of people and cannot predict what will happen to any individual person. Each patient’s situation is unique, and treatments continue to improve over time.^[2]

Grade 1 ependymomas, including subependymomas and myxopapillary ependymomas, generally have excellent survival rates when completely removed. Many patients with these slow-growing tumors live for many years or decades after diagnosis. Some patients have lived with ependymoma for over 30 years with proper treatment and monitoring.^[17]^[19]

For grade 2 ependymomas, outcomes depend heavily on whether complete surgical removal is achieved. When the entire tumor can be removed, many patients do well long-term. However, these tumors can recur, sometimes years after initial treatment, requiring additional surgery or other therapies.^[3]

Grade 3 anaplastic ependymomas have more variable outcomes. These aggressive tumors require intensive treatment, typically including surgery followed by radiation therapy. While more challenging to treat, some patients with grade 3 ependymomas respond well to treatment and achieve long-term survival. The molecular subtype and extent of surgical removal remain critical factors in determining outcomes.^[2]

Ependymomas rarely spread outside the central nervous system, which is somewhat encouraging compared to other cancers. When spread occurs, it’s usually within the brain and spinal cord through cerebrospinal fluid rather than to other organs in the body.^[4] This localized pattern of spread means treatment can focus on the nervous system.

#1 Clinical Trials Search in Europe